Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$4.89 -0.4%	$6.46	$3.79 ▼ $14.60	$230.98M	-0.95	1.47 million shs	874,725 shs
CDTX Cidara Therapeutics	$21.75 +4.1%	$20.94	$10.14 ▼ $28.42	$238.23M	0.89	71,564 shs	138,646 shs
CYCC Cyclacel Pharmaceuticals	$0.24 -5.3%	$0.27	$0.17 ▼ $3.15	$53.53M	0.15	1.57 million shs	2.09 million shs
DSGN Design Therapeutics	$4.71 -3.1%	$4.15	$2.60 ▼ $7.77	$267.35M	1.82	202,741 shs	215,383 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+1.45%	+2.61%	-13.10%	-29.45%	-30.35%
CDTX Cidara Therapeutics	-1.09%	-4.61%	-3.02%	+15.41%	+74.37%
CYCC Cyclacel Pharmaceuticals	-15.01%	+12.16%	-7.52%	-27.96%	-87.82%
DSGN Design Therapeutics	+10.71%	+19.41%	+25.91%	-2.21%	+38.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.2573 of 5 stars	3.5	1.0	0.0	2.7	2.5	0.6
CDTX Cidara Therapeutics	4.2409 of 5 stars	4.6	2.0	4.6	2.7	0.8	0.0
CYCC Cyclacel Pharmaceuticals	3.2851 of 5 stars	3.3	5.0	0.0	3.3	2.5	0.6
DSGN Design Therapeutics	1.8564 of 5 stars	3.3	0.0	0.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	329.45% Upside
CDTX Cidara Therapeutics	3.22	Buy	$39.14	79.97% Upside
CYCC Cyclacel Pharmaceuticals	2.50	Moderate Buy	$11.00	4,398.98% Upside
DSGN Design Therapeutics	2.50	Moderate Buy	$8.00	69.85% Upside

Current Analyst Ratings Breakdown

Latest CYCC, CADL, DSGN, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$46.00 ➝ $46.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/10/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/12/2025	CDTX Cidara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/12/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$46.00
3/12/2025	CDTX Cidara Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00
3/10/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $35.00
3/7/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
2/26/2025	CADL Candel Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $25.00
2/26/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	1,924.83	N/A	N/A	$0.44 per share	11.11
CDTX Cidara Therapeutics	$1.28M	186.85	N/A	N/A	($1.82) per share	-11.95
CYCC Cyclacel Pharmaceuticals	$74K	685.05	N/A	N/A	$0.57 per share	0.43
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$37.94M	-$1.75	N/A	N/A	N/A	N/A	-629.29%	-173.39%	5/13/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$30.09	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	5/8/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$3.50	N/A	∞	N/A	-18,150.00%	-1,901.11%	-188.23%	5/7/2025 (Estimated)
DSGN Design Therapeutics	-$66.86M	-$0.88	N/A	N/A	N/A	N/A	-18.01%	-17.38%	5/6/2025 (Estimated)

Latest CYCC, CADL, DSGN, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	CYCC Cyclacel Pharmaceuticals	-$0.29	N/A	N/A	N/A	$0.03 million	N/A
4/2/2025	Q4 2024	CYCC Cyclacel Pharmaceuticals	-$0.29	-$0.33	-$0.04	-$0.33	$0.01 million	$0.01 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	$0.15	61.35%	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest CYCC, CADL, DSGN, and CDTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/28/2025	CYCC Cyclacel Pharmaceuticals		$0.15		4/29/2025	4/29/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	N/A	1.18	1.18
CDTX Cidara Therapeutics	N/A	3.54	3.54
CYCC Cyclacel Pharmaceuticals	N/A	0.77	0.77
DSGN Design Therapeutics	N/A	34.61	34.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CDTX Cidara Therapeutics	35.82%
CYCC Cyclacel Pharmaceuticals	23.58%
DSGN Design Therapeutics	56.64%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	41.60%
CDTX Cidara Therapeutics	7.64%
CYCC Cyclacel Pharmaceuticals	68.00%
DSGN Design Therapeutics	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	47.24 million	18.97 million	Optionable
CDTX Cidara Therapeutics	90	10.95 million	6.51 million	No Data
CYCC Cyclacel Pharmaceuticals	14	207.34 million	4.78 million	Optionable
DSGN Design Therapeutics	40	56.76 million	38.96 million	Optionable

CYCC, CADL, DSGN, and CDTX Headlines

Recent News About These Companies

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

May 1 at 8:00 AM | globenewswire.com

Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%

April 25, 2025 | aaii.com

Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Purchased by Walleye Capital LLC

April 24, 2025 | marketbeat.com

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

April 22, 2025 | nasdaq.com

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 21, 2025 | globenewswire.com

Design Therapeutics appoints Chris Storgard as CMO

April 19, 2025 | markets.businessinsider.com

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

April 17, 2025 | globenewswire.com

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

April 17, 2025 | markets.businessinsider.com

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

March 12, 2025 | zacks.com

Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?

March 12, 2025 | msn.com

Design Therapeutics price target raised to $5 from $4 at RBC Capital

March 11, 2025 | markets.businessinsider.com

Design Therapeutics (DSGN) Gets a Hold from RBC Capital

March 11, 2025 | markets.businessinsider.com

Design Therapeutics sees cash runway into 2029

March 10, 2025 | markets.businessinsider.com

Design Therapeutics provides corporate highlights, anticipated milestones

March 10, 2025 | markets.businessinsider.com

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

March 10, 2025 | globenewswire.com

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

March 3, 2025 | markets.businessinsider.com

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

March 3, 2025 | globenewswire.com

Design Therapeutics: Not A Complete Washout Despite Setback

January 31, 2025 | seekingalpha.com

Design Therapeutics Updates Corporate Presentation for Investors

January 13, 2025 | tipranks.com

(DSGN) Investment Analysis

January 11, 2025 | news.stocktradersdaily.com

(DSGN) Trading Advice

December 31, 2024 | news.stocktradersdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCC, CADL, DSGN, and CDTX Company Descriptions

Candel Therapeutics NASDAQ:CADL

$4.89 -0.02 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$4.88 -0.01 (-0.20%)

As of 07:34 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cidara Therapeutics NASDAQ:CDTX

$21.75 +0.86 (+4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$21.73 -0.02 (-0.09%)

As of 04:05 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$0.24 -0.01 (-5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 0.00 (-0.20%)

As of 07:58 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Design Therapeutics NASDAQ:DSGN

$4.71 -0.15 (-3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$4.71 0.00 (0.00%)

As of 04:20 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time